Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) CEO Bobak R. Azamian sold 3,904 shares of the stock in a transaction dated Wednesday, January 11th. The shares were sold at an average price of $15.11, for a total transaction of $58,989.44. Following the completion of the transaction, the chief executive officer now owns 1,124,613 shares of the company’s stock, valued at approximately $16,992,902.43. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Tarsus Pharmaceuticals Price Performance
NASDAQ TARS traded down $0.03 on Friday, reaching $14.54. The company’s stock had a trading volume of 131,148 shares, compared to its average volume of 75,461. Tarsus Pharmaceuticals, Inc. has a twelve month low of $10.80 and a twelve month high of $21.47. The company has a debt-to-equity ratio of 0.10, a quick ratio of 16.40 and a current ratio of 16.40. The stock has a market cap of $387.81 million, a PE ratio of -5.23 and a beta of 0.67. The firm’s 50 day moving average is $15.84 and its two-hundred day moving average is $16.05.
Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) last issued its quarterly earnings results on Wednesday, November 9th. The company reported ($0.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.14. Tarsus Pharmaceuticals had a negative net margin of 324.99% and a negative return on equity of 34.24%. As a group, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -2.61 EPS for the current year.
Institutional Investors Weigh In On Tarsus Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its stake in Tarsus Pharmaceuticals by 221.0% during the first quarter. Dimensional Fund Advisors LP now owns 28,855 shares of the company’s stock valued at $485,000 after buying an additional 19,865 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Tarsus Pharmaceuticals by 3.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 48,583 shares of the company’s stock valued at $818,000 after buying an additional 1,402 shares in the last quarter. UBS Group AG lifted its stake in Tarsus Pharmaceuticals by 37.0% during the first quarter. UBS Group AG now owns 4,226 shares of the company’s stock valued at $71,000 after buying an additional 1,142 shares in the last quarter. Invesco Ltd. lifted its stake in Tarsus Pharmaceuticals by 17.1% during the first quarter. Invesco Ltd. now owns 27,982 shares of the company’s stock valued at $471,000 after buying an additional 4,078 shares in the last quarter. Finally, State Street Corp lifted its stake in Tarsus Pharmaceuticals by 2.4% during the first quarter. State Street Corp now owns 132,883 shares of the company’s stock valued at $2,235,000 after buying an additional 3,141 shares in the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Separately, Oppenheimer decreased their target price on shares of Tarsus Pharmaceuticals from $66.00 to $43.00 in a research report on Thursday, November 10th.
Tarsus Pharmaceuticals Company Profile
(Get Rating)
Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Featured Articles
- Get a free copy of the StockNews.com research report on Tarsus Pharmaceuticals (TARS)
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
- Carvana Stock Rally, Here’s What You Need to Know
- Will Oil Stocks Once Again Lead The Market As Inflation Eases?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tarsus Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Tarsus Pharmaceuticals wasn’t on the list.
While Tarsus Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we’ll send you MarketBeat’s guide to investing in 5G and which 5G stocks show the most promise.
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2023. All rights reserved.
© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.
